Case Based Panel Discussion -  Stage 3 NSCLC Best Schedule - Durvalumab/Imfinzi in Varying Patients

Case Based Panel Discussion - Stage 3 NSCLC Best Schedule - Durvalumab/Imfinzi in Varying Patients

User Photo
cancergrace

7 months
7 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC .




Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.

Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.

Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss the standard treatment of chemotherapy and radiation followed by immunotherapy and the best schedule for Durvalumab (Imfinzi) in a variety of patient scenarios.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Up Next Autoplay
>